Tahir Mahmood was co-founder of Mindera Health and co-invented and developed the company’s core technology platform. He is Chief Executive Officer and Co-founder at Applied Molecular Transport (NASDAQ: AMTI), a clinical stage biotech developing oral targeted biological therapeutics for treating immune-mediated inflammation, metabolic and other diseases. Previously, Tahir was a leader in the US West Coast Life Sciences practice at the management consulting firm Booz Allen Hamilton and was Managing Director at Lake Sherwood Partners. He was Visiting Investigator in the Department of Chemistry and Worm Institute for Research and Medicine at The Scripps Research Institute in La Jolla, CA and was previously Principal Business Analyst at Amgen, supporting R&D, and BD, M&A and strategic corporate venture fund transactions. Earlier, he was at Chienna (acquired by OctoPlus) and IsoTis S.A. (acquired by Integra Life Sciences).
Tahir has authored peer-reviewed publications and is inventor on issued and pending patents. He received a BASc in Mechanical Engineering and MSc in Biomedical Engineering from the University of Toronto, and holds a PhD in Chemical & Biomedical Engineering from a collaborative program between the University of Twente (The Netherlands) and MIT at the Harvard-MIT Division of Health Sciences and Technology and Children’s Hospital Boston.